(Q35193288)

7 August 2017

1 reference

title

STI571 as a targeted therapy for CML. (English)

1 reference

7 August 2017

1 reference

Michael E O'Dwyer

1

0 references

Brian Druker

object named as

Brian J Druker

series ordinal

3

0 references

author name string

Michael J Mauro

series ordinal

2

1 reference

7 August 2017

1 June 2003

1 reference

7 August 2017

1 reference

7 August 2017

21

1 reference

7 August 2017

429-438

1 reference

7 August 2017

3

1 reference

Chronic myelogenous leukemia: biology and therapy

7 August 2017

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Acute leukaemia in bcr/abl transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Involvement of platelet-derived growth factor in disease: development of specific antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018235

21 January 2018

Identifiers

DOI

10.1081/CNV-120018235

1 reference

7 August 2017

1 reference

PubMed ID

12901289